Certolizumab Pegol for Psoriasis and Psoriatic Arthritis
Sign Up to like & getrecommendations! Published in 2020 at "Current Dermatology Reports"
DOI: 10.1007/s13671-020-00298-y
Abstract: Purpose of Review The purpose of this review is to provide an overview of the use of certolizumab pegol (Cimzia®, UCB S.A.) for psoriasis and psoriatic arthritis and summarize important findings. Recent Findings Three pivotal… read more here.
Keywords: psoriasis; psoriatic arthritis; certolizumab pegol; psoriasis psoriatic ... See more keywords
Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis
Sign Up to like & getrecommendations! Published in 2020 at "Expert Review of Clinical Immunology"
DOI: 10.1080/1744666x.2020.1713754
Abstract: ABSTRACT Introduction: Certolizumab pegol (CZP) is an Fc-free PEGylated TNF-α inhibitor approved for the treatment of psoriatic arthritis (PsA) and plaque psoriasis in many countries. It demonstrated favorable results in PsA in terms of improvement… read more here.
Keywords: certolizumab pegol; plaque psoriasis; treatment; arthritis ... See more keywords
Safety and Effectiveness of Certolizumab Pegol in Japanese Patients with Rheumatoid Arthritis: Results from a 24-Week Post-Marketing Surveillance Study.
Sign Up to like & getrecommendations! Published in 2022 at "Modern rheumatology"
DOI: 10.1093/mr/roac073
Abstract: OBJECTIVES To report 24-week safety and effectiveness data of certolizumab pegol (CZP) in Japanese patients with rheumatoid arthritis (RA) from a post-marketing surveillance study. METHODS Enrolled patients were newly receiving CZP. All adverse events (AEs)… read more here.
Keywords: safety; japanese patients; safety effectiveness; certolizumab pegol ... See more keywords
Comparative analysis of low-field magnetic resonance imaging in patients with rheumatoid arthritis treated with certolizumab pegol or infliximab.
Sign Up to like & getrecommendations! Published in 2022 at "Modern rheumatology"
DOI: 10.1093/mr/roac138
Abstract: OBJECTIVE To clarify the differences in MRI findings between rheumatoid arthritis (RA) patients treated with Certolizumab pegol (CZP) and Infliximab (IFX). METHODS The study included RA patients who received CZP or IFX, and were examined… read more here.
Keywords: treated certolizumab; low field; rheumatoid arthritis; certolizumab pegol ... See more keywords
An open-label randomized controlled trial of DMARD withdrawal in RA patients achieving therapeutic response with certolizumab pegol combined with DMARDs.
Sign Up to like & getrecommendations! Published in 2019 at "Rheumatology"
DOI: 10.1093/rheumatology/kez470
Abstract: OBJECTIVES The objective of this trial was to compare effectiveness of certolizumab pegol added to conventional synthetic DMARDs (csDMARDs) in RA patients, followed by continuing vs discontinuing background csDMARDs after treatment response. METHODS Patients with… read more here.
Keywords: response; certolizumab pegol; patients achieving; pegol ... See more keywords
Vasculitis during certolizumab pegol and secukinumab treatment: Report of two cases
Sign Up to like & getrecommendations! Published in 2021 at "Dermatologic Therapy"
DOI: 10.1111/dth.15007
Abstract: Dear Editor, Tumor necrosis factor-alpha (TNF-α) inhibitors and interleukin-17 (IL17) inhibitors are widely used biologic agents in the treatment of several dermatologic and rheumatologic disorders including psoriasis (PsO), psoriatic arthritis, hidradenitis suppurativa (HS), and ankylosing… read more here.
Keywords: certolizumab pegol; treatment; tnf inhibitors; secukinumab ... See more keywords
Certolizumab pegol in the treatment of severe hidradenitis suppurativa after adalimumab failure: A real‐life experience
Sign Up to like & getrecommendations! Published in 2022 at "Dermatologic Therapy"
DOI: 10.1111/dth.15782
Abstract: There exists an unmet need to treat hidradenitis suppurativa (HS) despite several approved therapeutic agents for its treatment. We sought to investigate the role of certolizumab pegol in severe, recalcitrant HS patients unresponsive to adalimumab.… read more here.
Keywords: hidradenitis suppurativa; treatment; certolizumab pegol;
Psoriatic alopecia‐like paradoxical reaction to certolizumab pegol
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Dermatology"
DOI: 10.1111/ijd.14417
Abstract: Sweet syndrome are relevant differential diagnoses in this scenario. First-line treatment of rosacea fulminans includes the combination of isotretinoin and corticosteroids, the latter exceptionally used for rosacea management. The exact duration and cumulative doses necessary… read more here.
Keywords: paradoxical reaction; reaction certolizumab; certolizumab pegol; psoriatic alopecia ... See more keywords
THU0381 Certolizumab pegol is effective in uveitis associated to spondyloarthritis refractory to other tumour necrosis factor inhibitors
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.4425
Abstract: Background Uveitis is one of the most common extra-articular manifestations of patients with spondyloarthritis (SpA). In severe cases, uveitis may require the use of biological therapy, primarily tumor necrosis factors inhibitors (TNFi), being the most… read more here.
Keywords: spa; certolizumab pegol; treatment; uveitis associated ... See more keywords
FRI0130 Certolizumab pegol exposure during pregnancy in women with rheumatoid arthritis: evaluation of the long-term newborn outcomes
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.4632
Abstract: Background Increased TNF alpha (TNFα) levels have been associated to pregnancy complications such as intra-uterine growth retardation and fetal loss. Even if pregnancy has classically been considered as having a positive impact on RA, disease… read more here.
Keywords: ctz; pregnancy; pregnancy women; certolizumab pegol ... See more keywords
SAT0274 Retention rates of certolizumab pegol in ankylosing spondylitis and non-radiographic axial spondyloarthritis patients: hur-bio real life results
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.4649
Abstract: Background Drug survival rate is generally accepted as a reliable indicator of both efficacy and safety profile of a biological DMARD. Objectives To evaluate survival rates of certolizumab-pegol (CZP) in ankylosing spondylitis (AS) and non-radiographic… read more here.
Keywords: certolizumab pegol; hur bio; nraxspa patients; rates certolizumab ... See more keywords